The company is the third of the three major insulin manufacturers that dominate the U.S. market to announce such a move this month.

The company’s decision follows a similar move by its rival, Eli Lilly, this month.

With a history as a date rape drug, a medication needed strict distribution controls. Its maker, Jazz Pharmaceuticals, used that to delay competition.

AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and taxpayers. The monopoly is about to end.